Review
Copyright ©The Author(s) 2021.
World J Hepatol. Jan 27, 2022; 14(1): 98-118
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.98
Table 1 Genotype, phenotype and histopathological differentiation of the various types of progressive familial intrahepatic cholestasis

PFIC1
PFIC2
PFIC 3
Locus/gene/protein18q21-22/ATP8B1/FIC12q24/ABCB11/BSEP7q21/ABCB4/MDR3
Known mutations (n)150200300
Clinical profile
OnsetEarly onsetEarly onsetSecond decade
Age of presentation pruritus60% by 3 mo72% by 3 mo2-3 yr
JaundiceSevereSevereMild to none
CirrhosisSevere; By end of first decadeSevere; Majority within first 2 yr of lifeMild to moderate; By end of first decade
Growth failurePresent 90%Present 59%
OthersDiarrhea 61%; Pneumonia 13%; Pancreatitis 12%; Deafness 31%Gall stones in 32%Delayed puberty
ProgressionModerate rate of progressionRapidly progressiveHighly variable rate of progression
Associations with other cholestatic presentationsBRIC; ICPBRIC, DIC; ICP, HCCDIC, LPAC; ICP
Laboratory profile
TBAHighVery highHigh
GGTLow to normalLow to normalHigh
AST/ALTMild elevationModerate elevationMild elevation
AFPNormalHighNormal
Histopathology As disease progresses, periportal & pericentrilobular fibrosis develops; Leads to bridging fibrosis and micronodular cirrhosisCanalicular cholestasis, lobular/portal fibrosis and inflammation with giant cells; Severe hepatocellular necrosisPortal inflammation, portal fibrosis, cholestasis, ductular proliferation
ImmunohistochemistryCanalicular BSEP is normal or faint and MDR3 is normal bland intralobular cholestasisBSEP expression decreased to absent in the canalicular membraneMDR3 decreased to absent in the canalicular membrane